Clinical Trial Update: Phase I Study Evaluating TXA127 in Low/Intermediate-1 Risk Myelodysplastic Syndrome and Thrombocytopenia [Phase 1]

View source ↗

Summary

A Phase I study of TXA127 in patients with low/intermediate-1 risk myelodysplastic syndromes and thrombocytopenia was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes
• Thrombocytopenia

Drugs mentioned

• TXA127

Snippet

Sponsor: Tarix Pharmaceuticals | Conditions: Myelodysplastic Syndrome (MDS) | Phase 1 | Status: TERMINATED